Table 1

Characteristics of clinical, immunological, and virological parameters, and antiretroviral treatment of vertically HIV-1-infected children.

Previous-ART


N. of HIV-children

42

Age (years)(a)

6.7 ± 0.64 (0.5; 16.1)

Male(b)

16 (38.1%)

AIDS diagnosis (CDC)(b)

23 (54.7%)

Baseline CD4+cell count

% CD4+(a)

23.2 ± 1.8 (0.8; 49.7)

15 – 25% CD4+(b)

13 (22%)

<15 % CD4+(b)

16 (27.1%)

Baseline HIV-RNA level

log10 VL (copies/mL)(a)

4.52 ± 0.11 (3.22; 6.84)

VL >50,000 copies/mL(b)

14 (33.3%)

ART with NRTI prior-HAART(b)

Monotherapy

39 (92.9%)

Therapy combined

3 (7.1%)

HAART regimen at baseline(b)

3TC + d4T + NFV

27 (64.3%)

AZT + 3TC + NFV

6 (14.3%)

d4T + ddI + NFV

9 (21.49%)

New NRTI on HAART

0 NRTI

14 (33.3%)

1 NRTI

14 (33.3%)

2 NRTI

14 (33.3%)

HAART regimen during follow-up(b)

Global adherence (>90%)

100%

Change of drugs on first line of HAART

9 (21.4%)

Change of NRTI

2 (4.8%)

Adding a NNRTI

4 (9.5%)

Adding a PI

3 (7.1%)

Stop of HAART with NFV

16 (38.1%)

Change of NFV by other PI

12 (28.6%)

Interruption of HAART

4 (9.5%)


Values are expressed as: a) mean ± s.e.m. (min; max), and b) absolute (percentage). VL: viral load; CDC: Center for Disease Control. HAART: highly active antiretroviral therapy.

Resino et al. BMC Infectious Diseases 2006 6:107   doi:10.1186/1471-2334-6-107

Open Data